Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is a clinical-stage biotechnology company dedicated to developing therapies for patients with severe autoimmune diseases. The company's website is www.dianthustx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Dianthus Therapeutics, Inc. does
In the company’s own words
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is a clinical-stage biotechnology company dedicated to developing therapies for patients with severe autoimmune diseases. The company's website is www.dianthustx.com.
The company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody engineered with extended half-life and high selectivity for active C1s complement protein. Claseprubart is designed to enable less frequent, self-administered subcutaneous injections suitable for pre-filled pens. The company is currently conducting three mid- to late-stage clinical trials with claseprubart in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. In September 2025, the company reported positive top-line results from its Phase 2 MaGic trial in generalized myasthenia gravis patients, with plans to initiate a Phase 3 registrational trial in mid-2026. In March 2026, the company announced an early go announcement for its Phase 3 CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy after achieving target responder rates.
The company's second clinical-stage candidate, DNTH212, is a bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production while simultaneously inhibiting BAFF/APRIL to suppress B cell function. The company entered into an exclusive license agreement for DNTH212 in October 2025, with a Phase 1 study initiated in December 2025.
Dianthus was formed through a reverse merger completed on September 11, 2023, between Magenta Therapeutics, Inc. and Dianthus Therapeutics OpCo, Inc. The company holds worldwide development and commercialization rights to its product candidates outside of Greater China, where it has licensed claseprubart to Tenacia Biotechnology and DNTH212 to Nanjing Leads Biolabs. The company does not currently own manufacturing facilities and contracts with third parties for product manufacturing and distribution. As a smaller reporting company, Dianthus is classified as a non-accelerated filer with the Securities and Exchange Commission.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1690585
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Dianthus Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Dianthus Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Dianthus Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Dianthus Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Dianthus Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Dianthus Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”